Cargando…

A population-based comparison of patients with metastatic esophagogastric carcinoma between Japan and the Netherlands

PURPOSE: Differences exist between Asian and Western patients with esophagogastric cancer, for example in terms of histological subtype and treatment strategies. This study aimed to compare characteristics and treatment between patients with metastatic esophagogastric cancer from Japan and the Nethe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pape, Marieke, Vissers, Pauline A. J., Kato, Ken, Haj Mohammad, Nadia, Klarenbeek, Bastiaan, van Laarhoven, Hanneke W. M., Matsuda, Tomohiro, Verhoeven, Rob H. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587097/ https://www.ncbi.nlm.nih.gov/pubmed/37486395 http://dx.doi.org/10.1007/s00432-023-05111-4

Ejemplares similares

Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy
por: Pape, Marieke, et al.
Publicado: (2023)

A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma
por: Pape, Marieke, et al.
Publicado: (2022)

SOURCE beyond first‐line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first‐line palliative systemic therapy
por: Kuijper, Steven C., et al.
Publicado: (2022)

Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study
por: Kroese, Tiuri E., et al.
Publicado: (2022)

Population-based study of treatment and outcome of recurrent oesophageal or junctional cancer
por: Pape, Marieke, et al.
Publicado: (2022)

Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population‐based study
por: Pape, Marieke, et al.
Publicado: (2022)

A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
por: Pape, Marieke, et al.
Publicado: (2022)

Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
por: ter Veer, Emil, et al.
Publicado: (2016)

The impact of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer
por: Doeve, Benthe H., et al.
Publicado: (2023)

Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study
por: Pape, Marieke, et al.
Publicado: (2023)

Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review
por: ter Veer, Emil, et al.
Publicado: (2018)

Clinical variation in the organization of clinical pathways in esophagogastric cancer, a mixed method multiple case study
por: Luijten, J. C. H. B. M., et al.
Publicado: (2022)

Treatment decision‐making during outpatient clinic visit of patients with esophagogastric cancer. The perspectives of clinicians and patients, a mixed method, multiple case study
por: Luijten, Josianne C. H. B. M., et al.
Publicado: (2022)

Targeted Therapies for Metastatic Esophagogastric Cancer
por: Reddy, Deepa, et al.
Publicado: (2011)

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis
por: Haj Mohammad, N., et al.
Publicado: (2015)

Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients
por: Klaassen, Remy, et al.
Publicado: (2018)

Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
por: Dijksterhuis, Willemieke P. M., et al.
Publicado: (2020)

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)
por: Stroes, Charlotte I, et al.
Publicado: (2022)

Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer
por: van der Geest, Lydia G. M., et al.
Publicado: (2017)

Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands
por: Haj Mohammad, N., et al.
Publicado: (2016)

Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort
por: de Savornin Lohman, Elise, et al.
Publicado: (2020)

Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study
por: Keywani, Kammy, et al.
Publicado: (2023)

Are midwives in the Netherlands satisfied with their jobs? A systematic examination of satisfaction levels among hospital and primary-care midwives in the Netherlands
por: Cronie, Doug, et al.
Publicado: (2019)

Informing Patients With Esophagogastric Cancer About Treatment Outcomes by Using a Web-Based Tool and Training: Development and Evaluation Study
por: van de Water, Loïs F, et al.
Publicado: (2021)

Estimation of optimal birth weights and gestational ages for twin births in Japan
por: Kato, Noriko, et al.
Publicado: (2006)

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
por: Schokker, Sandor, et al.
Publicado: (2019)

Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
por: Werner, Dominique, et al.
Publicado: (2013)

Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data
por: Kankeu Fonkoua, Lionel Aurelien, et al.
Publicado: (2021)

SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
por: van den Boorn, Héctor G., et al.
Publicado: (2019)

Comparing the Health of Populations: Methods to Evaluate and Tailor Population Management Initiatives in the Netherlands
por: Hendrikx, Roy J.P., et al.
Publicado: (2018)

Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands
por: Dinmohamed, Avinash G, et al.
Publicado: (2020)

Rapid stromal remodeling by short‐term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma
por: Steins, Anne, et al.
Publicado: (2020)

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer
por: Derks, Sarah, et al.
Publicado: (2022)

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2023)

Unravelling the Homicide Drop: Disaggregating a 25-Year Homicide Trend in the Netherlands
por: Aarten, Pauline G.M., et al.
Publicado: (2021)

Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan
por: Fischer, M. J., et al.
Publicado: (2017)

Targeting EGFR in Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2020)

Diagnosis and Management of Esophagogastric Varices
por: Pallio, Socrate, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_feql6g6n9f7eh7i7ameta9c7bp